Ultragenyx Pharma (RARE) Posts Smaller-than-Expected Q2 Loss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Ultragenyx Pharma (RARE) PT Raised to $80 at Wedbush
August 6, 2018 7:50 AM EDTWedbush raised its price target on Ultragenyx Pharma (NASDAQ: RARE) to $80.00 (from $71.00) while maintaining a Outperform rating.
... MoreUltragenyx Pharma (RARE) PT Raised to $90 at Stifel
August 3, 2018 9:35 AM EDTStifel raised its price target on Ultragenyx Pharma (NASDAQ: RARE) to $90.00 (from $77.00) while maintaining a Buy rating.
... MoreUltragenyx Pharma (RARE) PT Raised to $85 at Piper Jaffray
August 3, 2018 6:01 AM EDTPiper Jaffray raised its price target on Ultragenyx Pharma (NASDAQ: RARE) to $85.00 (from $67.00) while maintaining a Overweight rating.
... More